Federal Register #2026-14133

Licensing Opportunity: Novel Pan Anti-HLA Monoclonal Antibodies for Cancer Immunotherapy

This opportunity from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), announces the availability for licensing of a novel government-owned invention: - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - OEMs and Vendors: - No commercial OEMs or vendors are specified; the technology is government-developed by NIAID/NIH - Products/Services Requested: - Licensing and collaborative research for novel pan anti-HLA monoclonal antibodies (3C10 and 15B1) - These antibodies block LILR inhibitory receptors and activate anti-tumor immunity - Intended for use in cancer immunotherapy and treatment of chronic infections (e.g., TB, HIV, hepatitis B or C) - Technology is in pre-clinical stage - No specific product quantities or part numbers; this is a licensing and research opportunity - Unique or Notable Requirements: - The antibodies target a broad immune pathway and bind more strongly to MHC I than previous antibodies (DX17 and W6/32) - Opportunity is for commercial development or further research collaboration, not direct procurement - No direct purchase or delivery of products is involved - Additional Note: - A separate announcement from the Office of Refugee Resettlement (ORR) under HHS increases the eligibility period for Refugee Cash Assistance and Refugee Medical Assistance from 4 to 8 months, but this is unrelated to the antibody licensing opportunity.

Description

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), announces the availability for licensing of a government-owned invention. The invention involves novel pan anti-HLA monoclonal antibodies that block LILR inhibitory receptors and activate anti-tumor immunity, designed to enhance cancer immunotherapy by releasing immune brakes on tumor-fighting cells. This technology is in the pre-clinical stage and is available for commercial development or further research collaboration. Licensing inquiries can be directed to the Technology Transfer and Intellectual Property Office at NIAID.

View original listing